StemCell Therapy

The healthcare provider organization is a crucial participant in a fast-evolving ecosystem around precision medicine, which includes pharma and biotech companies, medical device manufacturers, national research organizations, academic medical centers, patient advocacy groups, and others.

According to the Precision Medicine Initiative, precision medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyles.

Precision medicine and personalized medicine often are used interchangeably, but have slightly different connotations with the former focused more on the clinical realm of genomics and the latter taking a more expansive view of social and behavioral health.

Both hold huge potential for better health outcomes but also require complex and challenging technology deployments, changes to clinical workflow, and education for physicians and patients alike.

It is important that the provider CIO help to lead their organization into this new world by considering how existing technologies can be optimized and how new, disruptive technologies can be anticipated over multiple years of capital budget investments, said Dan Kinsella, managing director, healthcare and life science, at consulting giant Deloitte.

Of paramount importance to the typical provider CIO is how to operationalize precision medicine at the point of care. There is not a one-size-fits-all solution for healthcare providers, but there are leading practices to consider whether you are an academic medical center, an integrated delivery network or a community hospital.

In this special report, seven precision medicine technology experts from Accenture, CereCore, Chilmark Research, Deloitte and Orion Health offer healthcare provider organization CIOs and other health IT leaders best practices for optimizing this technology.

Some optimization techniques for precision medicine technologies can take place during system implementation. Implementing precision medicine technology is no different from any other IT implementation project, said Ian McCrae, CEO of Orion Health, a healthcare technology company delivering interoperability, population health and precision medicine systems.

Healthcare CIOs and other health IT leaders must get the basics of change management right by following seven steps, McCrae advised.

Ian McCrae, Orion Health

First, know what problem you are trying to solve, he said. Have this clearly defined from the outset. Dont make the mistake of trying to implement the tech if you havent identified what you will be using it for. Second, ensure the solution makes life easier and delivers a better outcome. If the project fails in either of these areas, then it will fail overall. If the precision medicine tech doesnt make life easier for clinicians, or deliver a better outcome for patients, then why are you implementing it?

Third, have clear roles and responsibilities, including data stewardship, governance and ethics, he suggested. The principles of data governance and stewardship are critical, and must not be overlooked if a project is to be successful, he said.

What are your guidelines for governing the data you will extract? he asked. These guidelines should be clearly aligned with your organizations strategic vision and values. Ethics of data use is another critical area: informed patient consent, the right to withdraw, confidentiality, objectivity the list is long.

Fourth, CIOs need to connect the dots with precision medicine technologies, McCrae advised.

Providing a better prediction without a means to act on it will be a recipe for frustration, he said. Once you have the technology to enable improved predictions, will you also have the resources to apply the learnings? If you cant deliver a better outcome for patients, then its likely your project will fail. Fifth, remember accuracy isnt necessarily the most important thing.

We often compare solutions by how often they get the answer right, without understanding what people want to do with the answer, he added. Knowing that someone is 61.3% likely to get cancer versus 59.8% isnt as important as how quickly you can know it, and what you can do when you find out.

Sixth, stick to the plan and do not get distracted by failures along the way, he said.

We find it hard to continue the development of something when the first stage isnt as successful as we had hoped, he noted. If we are aiming to make precision medicine the gold standard across different fields but the first application isnt successful, that doesnt mean you should throw out the goal.

And seventh, start with specialties where the application is clear, said McCrae. Rather than aiming to implement the tech into a multitude of areas, select one or two specialties where the value of precision medicine is clear. Learn from those before expanding into new areas.

Dr. Charles Bell, chief medical officer at CereCore, a health IT consulting firm, advised that getting the foundational infrastructure established before precision medicine can be applied via the EHR is one best practice for optimizing the use of the technology.

Precision medicine relies on genomics genomics, including pharmacogenomics, has created a vast amount of data, whereas the advent of the EHR has established an enormous data repository, he said. The success of advancing the technology is dependent on the genomic data residing in a repository that the EHR can readily provide access to. Therefore, there is a foundational infrastructure that must be established before precision medicine can be applied leveraging the EHR platforms.

Dr. Charles Bell, CereCore

Genomic medicine is currently informing clinical care. Notable examples are in the treatment of some cancer types, cystic fibrosis and heart disease.

The integration of the EHR, the data repository and the genomics medicine platform becomes essential to translate relevant and crucial data to drive precision medicine care, Bell said. A streamlined workflow must be established that allows clinicians to provide appropriate care from within the EHR using genomics and precision medicine.

Precision medicine requires capturing and analyzing complex data so that it is actionable at the point of care. Evolution of clinician workflow to support precision medicine use cases even those that are relatively simple, such as pharmacogenomics requires multidisciplinary change-management efforts and thoughtful systems integration, said Kinsella of Deloitte.

Furthermore, the challenges of leveraging next-gen sequencing data in clinical decision support exceeds the capability of current EHR systems, except in certain use-cases such as pharmacogenomics, said Kinsellas colleague Connor OBrien, manager at Deloitte Consulting.

Dan Kinsella, Deloitte

This requires external decision support analysis, which often is a manual process, such as the outputs of diagnostic review boards, although we are seeing many attempts at automation being applied, such as the decision-support platforms being deployed by GenomOncology, 2bPrecise, Syapse and others.

When it comes to oncology and other service line roadmaps, health IT leaders should work with their service-line leaders to understand any gaps they have in the technology required to enable excellence in care delivery, Kinsella suggested.

With oncology specifically, ensure that genomic requirements are understood as the capital investments may require multiple fiscal years, he said. Refine your technology roadmap for tumor boards as the future state is likely to include a variety of external contributors such as leading academic medical centers and drug and biotech companies.

Then there are social determinants of health (SDoH). Precision requires understanding of variability in environment and lifestyle in addition to genetics. While most provider organizations are oriented to patients, expansion to the notion of member as an individual who may or may not have a medical record is required, Kinsella insisted.

Value-based contracts with payers define specific cohorts (members) for whom the provider has assumed a level of accountability, he explained. Background and lifestyle questions not typically the focus of most EHR-centric workflows are crucial to the personalization of the care we deliver.

With precision medicine comeinstitutional alliance relationships, said Kinsellas colleague Kate Liebelt, a manager with the Precision Medicine Community of Practice at Deloitte Consulting.

In addition to having the logo on your website, what is the essence of your relationships with your external partners? she asked. Are you sending your data out to a registry without distilling the value of that information for care of your own patients? Increasingly, providers are licensing proprietary data to industry partners. For example, Cancer Commons is a not-for-profit network focused on connecting patients, physicians and providers to access cutting-edge personalized treatments beyond the traditional standard of care, through data sharing.

Entities like the Texas Medical Center Accelerator harness innovation and talent from area healthcare organizations and generate start-up companies with regional, local and international reach, she added.

Real-world evidence is driving innovation in value-based contracting and reimbursement strategies as demonstrated by the CMS Oncology Care Model a new payment and delivery model designed to improve the effectiveness and efficiency of specialty care, she explained. Enablement of precision medicine helps AMCs continue to meet their tripartite mission of education, care delivery and research.

And on a related note, interoperability. Sending and receiving data from across the evolving ecosystem requires that one be at the top of one's game regarding interoperability and, importantly, cybersecurity and compliance from FTTP, to HL7, to FHIR APIand beyond, OBrien said.

Dont leave out your CISO or legal and compliance teams, he said. Current architectures integrate insights from external clinical-decision-support systems, with the EHR serving as the transactional system of record:insights derived from external decision support FHIR API-based integrations that trigger EHR transactions such as pre-populated order sets, modifications to problem lists, and incorporation of CLIA test reports into clinical documentation modules in EHRs.

Jody Ranck, senior analyst at Chilmark Research, a healthcare IT research and consulting firm, advised that integration of genomic data across different EHR systems and across different laboratory and precision medicine platforms is key and challenging for most organizations.

Genetic test results tend to be large files that are difficult to integrate into an EHR, he said. Therefore, having a road map for your precision medicine approach is essential to think ahead several years and analyze which clinical areas will be impacted by the precision medicine program first. Oncology tends to be the most well-developed area, but in our COVID-19 moment, we may see the need for adjustments as significant caseloads of patients are those recovering from treatment with long-term challenges and new knowledge of the virus expands.

Jody Ranck, Chilmark Research

The impact of the pandemic on precision medicine may have some long-term consequences for best practices.

There will be a distributional shift of baseline health characteristics at the population level for the datasets that machine learning algorithms were trained on and new features to these populations that may interact with specific precision medicine initiatives, Ranck said.

The pandemic also has highlighted how poorly prepared the health IT infrastructure was for a public health crisis. Future federal funding, if funded wisely, will have significant funding to enhance precision public health initiatives, particularly those that bring social determinants into the picture. CIOs will face growing pressure to find effective ways to leverage and enhance SDoH efforts through more precise allocation knowledge and financial resources to address the sequelae of the pandemic.

One best practice for optimizing precision medicine technology is to create integration standards that support treatment across ambulatory and inpatient settings, said Bell of CereCore.

The large amount of data that has been generated in both the ambulatory and inpatient settings creates a challenge for integration of the information, he said.

Standards need to be established and refined to aid in the adoption of the technology that will support precision medicine. Clinical-decision-support capabilities must be integrated within the EHR. The evolution of the use of genomics to support precision medicine is dependent on collaborative development by multiple stakeholders.

The list of requirements includes, but is not limited to, genomics specifications, clinical decision support, systems capable of handling genomic information, and resources to bridge the gaps between the data and its use clinically, he added.

An example of the use of pharmacogenetics is that of Warfarin dosing, he said. For a decade now, recommendations for Warfarin dose requirements have been influenced by gene studies. Though there continue to be questions of the effect on specific genotypes in some patient populations, there still has been an improvement in treatment of identified patients with warfarin therapy. The result is that information is gained for a more effective treatment plan and a decreased risk of potentially harmful side effects.

The more specific needs of varied patient populations can be addressed with further use of genetic data that is standardized across the patients settings, he added.

Most EHRs offer a genomics solution to address providers workflow, Bell noted. An order is entered into the system and a pathway provides information to enhance clinical decision-making. It takes into account clinical decision support as well as alternatives if genomic results do not exist or are not accessed within the system. For all vendors, including Meditech, Cerner and Epic, storage and access to genomic repositories needs to be resolved.

eMerge and ClinGen are examples of organizations, along with other resources and efforts, that are developing approaches to integrate genomic information into precise clinical care, he added.

To enable precision medicine, leading provider organizations are refreshing their existing analytics strategies, and hardening core data-management capabilities, said Kinsella of Deloitte. Note that analytics includes descriptive (reports on what happened yesterday), predictive (what might happen in the future) and prescriptive (for example, precision medicine leading practices), he explained.

Regarding reference architecture, use what you have, buy what you need and build what you must, Kinsella said. Explore the capabilities of your core enterprise applications including EHR, ERP and cost accounting, and adjust known levers for example, clinical-decision-support capabilities, lab-management systems, and billing and coding management to operationalize a precision medicine program. Focus on the tools you may require to ensure collection, curation, calculation and consumption of data to generate analytic insights.

On a related front, there are edge technologies and big data. By leveraging open source and edge solutions, providers can augment legacy analytics and data management capacity, Deloittes OBrien said.

For example, providers increasingly are commissioning data lakes to collect and curate data from a variety of internal and external sources, he noted. The velocity of data, including streaming, enables monitoring (for example, sepsis data),disease management and population health surveillance (for example, SDoH), and remote patient-monitoring, tapping into the tsunami of data generated from wearables and IoT.

The need for analysis provenance and traceability of results becomes amplified when dealing with molecular-level data, due to the dynamic nature of scientific discovery, he added.

Genomic variants that are classified as variants of unknown significance today can become clinically significant as scientific knowledge progresses, he said. These requirements will become even more critical as more dynamic types of omics data become clinically significant, such as being realized in the case of metabolomic and proteomic data. Put simply, todays information exhaust may become tomorrows rocket fuel.

In the continuous pursuit of data excellence, CIOs should collaborate with CMIOs, CNIOs and clinical informatics to ensure that key data elements are understood, configured to be captured by the enterprise applications, and, most important, align the workflow so that data is collected predictably, Kinsella said.

Registries, often a standard feature of enterprise EHRs, represent untapped potential, he noted. Typical features include definition of inclusion rules and calculation instructions for specific cohorts of patients. When, for example, does a diabetic patient get tagged as a diabetic patient in the diabetes registry?

Threaded throughout the emerging theme of precision medicine enablement is education around analytics: training in data science, and the application of descriptive, predictive and prescriptive analytics, he added. Increasingly, provider organizations are hiring in-house analytics experts and partnering with entities on their data strategies and capabilities, he said.

Review your organization strategy and align your data sharing approach accordingly, added Deloittes Liebelt. Are you motivated by social good? Academic pursuit of new science? Are you open to earning revenue by sharing de-identified data by building bandwidth to drive robust real-world evidence programs and innovative industry partnerships?

Patient registries and patient-reported outcomes-measurement are a significant means of value creation for provider organizations, particularly in the areas of oncology, rare and orphan disease, and chronic disease management, she said.

Theoretically, providers can predict and validate a patients predisposition to diabetes and track and measure their progress on various treatment regiments through the systematic collection of patient data, for example, population-level data, lab results, patient-reported outcomes, etc., she explained.

As providers continue to make their real-world data available in open, closed or hybrid networks, there is an emergence of innovative partnership opportunities with other provider organizations, pharmaceutical/biotechnology/medical device companies, health insurance companies, and publicly and privately funded research institutions.

On another front, precision medicine is a significant mind-shift for both patients and providers, and the integration of genomic data, or more importantly, knowledge, is a significant challenge, said Ranck of Chilmark Research.

The process of obtaining genetic information is not always as straightforward,and interpreting these results for a patient can be difficult, he said. Most diseases are not a one gene equals X disease type of phenomenon.

Physicians will need more time to digest precision medicine data and render this into actionable information for the patient, he said.

In the context of standard clinical workflows, this is a challenge, he observed. However, there are platforms that can reduce the burden for physicians, but rigorous evaluation of these solutions and the underlying science needs to be done by physicians and scientists with sufficient knowledge of statistics, machine learning and genetics.

Genetic counselors will be essential and may not be in adequate supply as precision medicine matures, he added. Precision medicine is not solely a technological issue and needs to be understood as socio-technical in nature.

Dr. Kaveh Safavi, senior managing director at Accenture Health, offers two best practices when trying to optimize precision medicine technology.

Good clinical practice today needs therapy to be tailored to the genetics of the tumor and the patients immune system for many types of cancer, he explained.

Dr. Kaveh Safavi, Accenture Health

From a CIO perspective, precision medicine achievements mean building a new environment for data acquisition, analysis and decision support in near real time. Oncology decision-support platforms will require managing genetic information of the patient, the patients tumor and other phenotypic data that may not be part of the typical electronic health record.

Since much of oncology care is provided in an ambulatory setting, it also will require seamless data sharing across care settings that may cross boundaries of a clinical enterprise but be essential to treating a patients condition in the most appropriate way possible, Safavi said.

And on another note, there is a growing body of knowledge that combines pharmacology and genomics to develop effective and safe medications and doses tailored to a patients genetic makeup, he said. A delicate part of a CIOs responsibility is selecting and investing in an informatics strategy to support this highly dynamic aspect of clinical care.

An informed drug-prescribing platform requires the ability to gather biological information found in genomes, microbiomes, proteomes, metabolomes, phenotypes and endotypes, he concluded, and applying them to drug-prescribing decision-support platforms used by prescribers should take into account looking for technology architectures with the greatest flexibility to predictably handle large data volumes and data types.

Twitter:@SiwickiHealthITEmail the writer:bill.siwicki@himssmedia.comHealthcare IT News is a HIMSS Media publication.

Continued here:
Tech optimization: Unlocking the promise of precision medicine - Healthcare IT News

MAASTRICHT, Netherlands, May 13, 2020 /PRNewswire/ --The Department of Precision Medicine atMaastricht University(The Netherlands) announced today the release of their AI tool for COVID-19 patient triage,the same week that they received 920K from the European Commission for the DRAGON project (link: information on the grant).

The D-Lab group of the Dpt of Precision Medicine is developing a personalized medicine platform to enable risk assessment of COVID-19 patients. The models, made by the group or published elsewhere, are available world-wide on their new platform https://covid19risk.ai

"We are excited to be participating in the global fight against the COVID-19 pandemic with our Decision Support System for Risk Assessment of COVID-19 patients. We have repurposed our AI methods, usually applied to oncology questions, to the COVID-19 pandemic," said Prof. Philippe Lambin, Department Head. The platform can integrate various types of medical data available as well as assess the risk of severe disease that requires mechanical ventilation.

"We also have simple models to identify vulnerable patients that should follow a strict lockdown, which include, for example, not doing their groceries themselves if they are over the age of 64 and have high blood pressure," said Dr. Avishek Chatterjee.

The recently funded European project DRAGON will achieve a patient empowerment centred decision support system that will enable multiple stakeholders to participate in improved and more rapid diagnosis, as well as the potential of precision medicine for accelerated development of new therapies.

Dr. Cary Oberije, head of the Virtual Trial Unit of the Dpt of Precision Medicine, added: "One of our missions will be to coordinate an international prospective biomarker trial on COVID-19 patients. We want to understand this virus better and use this knowledge for future outbreaks, also for other viruses."

The entire effort will be supported by the deployment of a federated machine learning system, a technology developed in Maastricht by Prof Lambin's group, that will allow for the GDPR compliant use of multinational data resources.

About the Dpt of Precision Medicine

The Department of Precision Medicine is a disease-agnostic AI department with an international group of researchers at Maastricht University. For more information visit http://www.precisionmedicinemaastricht.eu.

SOURCE Dpt of Precision Medicine, Maastricht University

Visit link:
The Department of Precision Medicine of Maastricht University Receives 920K from the European Commission to Further Develop Their Work on Artificial...

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

This report provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/y88s2r

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Metabolic Partnering Deals Collection 2014-2020: Access to Over 950 Deal Records - PRNewswire

[I]t is never too soon to think of a post-corona world, he writes, where new technologies and medical fields such as digital health can coexist in greater harmony with, and due attention to, social justice and ecological determinants of health than the pre-corona world.

Digital health, zdemir also notes, builds on the concept and theory of cyber-physical systems that create a digital replica of all living and inanimate objects on the planet.

Representative article titles in the issue include New Machine Learning Applications to Accelerate Personalized Medicine in Breast Cancer: Rise of the Support Vector Machines, Integrating Artificial and Human Intelligence: A Partnership for Responsible Innovation in Biomedical Engineering and Medicine and Implementing Artificial Intelligence and Digital Health in Resource-Limited Settings? Top 10 Lessons We Learned in Congenital Heart Defects and Cardiology.

To access the all-free issue, click here.

Read the original post:
When the pandemic is in the past, will digital health have gained much ground? - AI in Healthcare

Dublin, May 15, 2020 (GLOBE NEWSWIRE) -- The "Artificial Intelligence Markets in IVD" report has been added to ResearchAndMarkets.com's offering.

This report examines selected AI-based initiatives, collaborations, and tests in various in vitro diagnostic (IVD) market segments.

Artificial Intelligence Markets in IVD contains the following important data points:

The past few years have seen extraordinary advances in artificial intelligence (AI) in clinical medicine. More products have been cleared for clinical use, more new research-use-only applications have come to market and many more are in development.

In recent years, diagnostics companies - in collaboration with AI companies - have begun implementing increasingly sophisticated machine learning techniques to improve the power of data analysis for patient care. The goal is to use developed algorithms to standardize and aid interpretation of test data by any medical professional irrespective of expertise. This way AI technology can assist pathologists, laboratorians, and clinicians in complex decision-making.

Digital pathology products and diabetes management devices were the first to come to market with data interpretation applications. The last few years have seen the use of AI interpretation apps extended to a broader range of products including microbiology, disease genetics, and cancer precision medicine.

This report will review some of the AI-linked tests and test services that have come to market and others that are in development in some of the following market segments:

Applications of AI are evolving that predict outcomes such as diagnosis, death, or hospital readmission; that improve upon standard risk assessment tools; that elucidate factors that contribute to disease progression; or that advance personalized medicine by predicting a patient's response to treatment. AI tools are in use and in development to review data and to uncover patterns in the data that can be used to improve analyses and uncover inefficiencies. Many enterprises are joining this effort.

The following are among the companies and institutions whose innovations are featured in Artificial Intelligence Markets in IVD:

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Artificial Intelligence In Diagnostics Markets

Chapter 3: Market Analysis: Artificial Intelligence in Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/vw8l7u

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Here is the original post:
Artificial Intelligence Markets in IVD, 2019-2024: Breakdown by Application and Component - GlobeNewswire

NEW YORK--(BUSINESS WIRE)--Flatiron Health, Foundation Medicine, and Genentech, a member of the Roche Group, in partnership with community and academic oncology practices, have launched the Prospective Clinico-Genomic (PCG) Study, NCT04180176. PCG is a novel, low-interventional study that will pilot the use of a technology-enabled prospective data collection platform to facilitate, streamline and simplify the execution of clinical trials for patients living with advanced lung cancer.

The PCG Study, funded and sponsored by Genentech, is a feasibility study with secondary aims to better understand how genomic changes in a patients tumor may predict response or impact resistance to treatment in people diagnosed with metastatic non-small cell lung cancer or extensive stage small cell lung cancer by building a linked data- and bio-repository. Flatirons prospective real-world data collection technology will be leveraged for this study, which will enroll approximately 1,000 patients. These patients will undergo serial liquid biopsies using Foundation Medicines liquid biopsy assay to assess genomic changes in their cancer over the course of treatment. Leveraging technology developed following years of collaboration between Flatiron and Foundation Medicine, the clinical, genomic, imaging and outcomes data will be a part of a comprehensive data platform that is designed to accelerate research, a central part of Roches vision for personalized healthcare.

Through technology-driven innovation, we have realized our vision of building a platform that enables meaningful clinical research while also minimizing the burden on clinicians and research teams. This includes features such as centralized and remote study monitoring, streamlined patient identification, and technology-assisted abstraction to eliminate duplicate data entry and the need to use a separate electronic data capture system, said Dr. Bobby Green, chief medical officer at Flatiron Health. Our goal is to bring vital clinical research to patients where their care is already being delivered, and to do so efficiently and seamlessly.

Since launching the study in December 2019, 14 practices from Flatirons network have been activated: Alabama Oncology, Cancer & Hematology Centers of Western Michigan, Clearview Cancer Institute, Fort Wayne Medical Oncology and Hematology, Hematology Oncology Associates of Central New York, Hematology Oncology Associates of Fredericksburg, Highlands Oncology Group, Jackson Oncology Associates in Mississippi, New York Cancer & Blood Specialists, Oklahoma Cancer Specialists and Research Institute, RCCA-Central Jersey, Southeast Nebraska Cancer Center, Virginia Cancer Institute, and West Cancer Center. Additional research sites are planned over time.

Clinical trials are critically important to advancing cancer research, but the way trials are run has in many ways not changed in decades, and continues to be burdensome and time-consuming, said Dr. Lee Schwartzberg, chief medical officer at OneOncology, and physician at West Cancer Center. The PCG Study has the potential to help transform how clinical trials are conducted, ultimately making research more feasible for all sites and increasing the number of trial opportunities for patients. We hope that the study design and technology deployed in PCG will ultimately become standard practice and used across a wide swath of trials.

"We've been a part of this study since December, and it is an exciting opportunity to be a part of building this research platform. While this study is expected to help patients in the future, it also provides important information for our enrolled patients invaluable to their current management, shared Dr. Eric Santos, physician at Cancer & Hematology Centers of Western Michigan.

Using new platforms to accelerate the development and delivery of the best possible medicines for every type of patient is central to our vision for personalized healthcare, said Mark Lee, global head of personalized healthcare, product development, at Genentech. The PCG Study represents an important step toward the next iteration of the clinical research ecosystem, opening up opportunities to extend clinical trials into the real world setting to more investigators and more patients than ever before."

At this years ASCO Virtual Scientific Program, Genentech, Flatiron, Foundation Medicine and co-authors will present the study design and objectives in a Trials-In-Progress abstract titled, A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.

To learn more about the PCG Study, contact PCG@flatiron.com.

About Flatiron Health

Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit http://www.flatiron.com or follow us @FlatironHealth.

More:
Flatiron Health, Foundation Medicine and Genentech Partner to Launch Novel Prospective Lung Cancer Clinical Study - Business Wire

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Nucleic Acid Amplification Testing market. It informs readers about key trends and opportunities in the global Nucleic Acid Amplification Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1766968/covid-19-impact-on-nucleic-acid-amplification-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nucleic Acid Amplification Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Nucleic Acid Amplification Testing Market Segment By Type:

,Target Amplification Systems,Probe Amplification Systems,Signal Amplification

Global Nucleic Acid Amplification Testing Market Segment By Application:

,Infectious Diseases,Cancer,Personalized Medicine,Genetic and Mitochondrial Disorders

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories, etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1766968/covid-19-impact-on-nucleic-acid-amplification-testing-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Nucleic Acid Amplification Testing Industry1.7 COVID-19 Impact: Nucleic Acid Amplification Testing Market Trends 2 Global Nucleic Acid Amplification Testing Quarterly Market Size Analysis2.1 Nucleic Acid Amplification Testing Business Impact Assessment COVID-192.1.1 Global Nucleic Acid Amplification Testing Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Nucleic Acid Amplification Testing Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Nucleic Acid Amplification Testing Quarterly Market Size, 2019 VS 20203.2 By Players, Nucleic Acid Amplification Testing Headquarters and Area Served3.3 Date of Key Players Enter into Nucleic Acid Amplification Testing Market3.4 Key Players Nucleic Acid Amplification Testing Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Nucleic Acid Amplification Testing Segments, By Type4.1 Introduction1.4.1 Target Amplification Systems1.4.2 Probe Amplification Systems1.4.3 Signal Amplification4.2 By Type, Global Nucleic Acid Amplification Testing Market Size, 2019-2021 5 Impact of Covid-19 on Nucleic Acid Amplification Testing Segments, By Application5.1 Overview5.5.1 Infectious Diseases5.5.2 Cancer5.5.3 Personalized Medicine5.5.4 Genetic and Mitochondrial Disorders5.2 By Application, Global Nucleic Acid Amplification Testing Market Size, 2019-20215.2.1 By Application, Global Nucleic Acid Amplification Testing Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 F. Hoffmann-La Roche7.1.1 F. Hoffmann-La Roche Business Overview7.1.2 F. Hoffmann-La Roche Nucleic Acid Amplification Testing Quarterly Revenue, 20207.1.3 F. Hoffmann-La Roche Nucleic Acid Amplification Testing Product Introduction7.1.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments7.2 Becton7.2.1 Becton Business Overview7.2.2 Becton Nucleic Acid Amplification Testing Quarterly Revenue, 20207.2.3 Becton Nucleic Acid Amplification Testing Product Introduction7.2.4 Becton Response to COVID-19 and Related Developments7.3 Dickinson and Company7.3.1 Dickinson and Company Business Overview7.3.2 Dickinson and Company Nucleic Acid Amplification Testing Quarterly Revenue, 20207.3.3 Dickinson and Company Nucleic Acid Amplification Testing Product Introduction7.3.4 Dickinson and Company Response to COVID-19 and Related Developments7.4 Beckman Coulter7.4.1 Beckman Coulter Business Overview7.4.2 Beckman Coulter Nucleic Acid Amplification Testing Quarterly Revenue, 20207.4.3 Beckman Coulter Nucleic Acid Amplification Testing Product Introduction7.4.4 Beckman Coulter Response to COVID-19 and Related Developments7.5 Abbott Laboratories7.5.1 Abbott Laboratories Business Overview7.5.2 Abbott Laboratories Nucleic Acid Amplification Testing Quarterly Revenue, 20207.5.3 Abbott Laboratories Nucleic Acid Amplification Testing Product Introduction7.5.4 Abbott Laboratories Response to COVID-19 and Related Developments7.6 Illumina7.6.1 Illumina Business Overview7.6.2 Illumina Nucleic Acid Amplification Testing Quarterly Revenue, 20207.6.3 Illumina Nucleic Acid Amplification Testing Product Introduction7.6.4 Illumina Response to COVID-19 and Related Developments7.7 Siemens Healthineers7.7.1 Siemens Healthineers Business Overview7.7.2 Siemens Healthineers Nucleic Acid Amplification Testing Quarterly Revenue, 20207.7.3 Siemens Healthineers Nucleic Acid Amplification Testing Product Introduction7.7.4 Siemens Healthineers Response to COVID-19 and Related Developments7.8 bioMerieux7.8.1 bioMerieux Business Overview7.8.2 bioMerieux Nucleic Acid Amplification Testing Quarterly Revenue, 20207.8.3 bioMerieux Nucleic Acid Amplification Testing Product Introduction7.8.4 bioMerieux Response to COVID-19 and Related Developments7.9 Novartis7.9.1 Novartis Business Overview7.9.2 Novartis Nucleic Acid Amplification Testing Quarterly Revenue, 20207.9.3 Novartis Nucleic Acid Amplification Testing Product Introduction7.9.4 Novartis Response to COVID-19 and Related Developments7.10 Bio-Rad Laboratories7.10.1 Bio-Rad Laboratories Business Overview7.10.2 Bio-Rad Laboratories Nucleic Acid Amplification Testing Quarterly Revenue, 20207.10.3 Bio-Rad Laboratories Nucleic Acid Amplification Testing Product Introduction7.10.4 Bio-Rad Laboratories Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post here:
Nucleic Acid Amplification Testing Market 2020-2026: Key Vendor Landscape By Regional Output, Demand By Countries And Future Growth - Cole of Duty

In recent years, targeted cancer therapies have increased in use. These individualized treatments are based on the genetic makeup of a patient's disease.

Precision medicine in cancer is characterized by these personalized therapies, and it is tailored to address potential genetic changes in a patients tumor. By directly attacking the tumor, the researchers stress the impact this can have in protecting healthy cells that are also damaged during chemotherapy and radiotherapy, which can lead to severe toxicity in healthy tissues.

The researchers sought to provide an outline of emerging developments in targeted cancer therapy, particularly 2 areas of interest: immune-based therapy and enzyme-/small moleculesbased therapies. They included advancements in cancer targeted therapy, personalized medicine, and cancer combination therapies from research papers published from 2010 to June 2019.

Immune-Based Therapy

As the study authors discuss, immunotherapy-based strategies differ from both chemotherapy and radiotherapy-based treatments. Instead of directly attacking the growth of the cancer, the approach enhances the immune response to the cancer. Several notable innovations have increased the availability of this strategy, including immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens, and ligand targeted therapeutics.

ICIs have served as major advancements in oncology, with several already approved by the FDA. Although their impact in revolutionizing the treatment of cancer has been noted, there have also been reports they could cause serious harm to patients due to their toxicity, with some recipients reporting immune-related adverse events. The researchers highlight that further studies are warranted to gain a detailed understanding of tumors' mechanisms of resistance to checkpoint inhibitors treatment, in order to improve the therapy.

Enzyme-/Small MoleculesBased Therapies

In enzyme-/small moleculesbased therapies, the researchers cited innovations, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates, and antibody-directed enzyme prodrug therapy.

The PROTAC strategy has been expanded and utilized in the treatment of many diseases, including ER-positive breast cancer, and to target steroid hormone receptors for ubiquitination and degradation in breast and prostate cancers.

As the researchers note, the approach is inspired by a mechanism in which the cell degrades unwanted proteins and consists of a molecule with 2 independent moieties. Recently, PROTAC was used to degrade the anaplastic lymphoma kinase, which has been associated with several types of human cancer.

The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies, said the study authors.

Reference

Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine [published online February 25, 2020]. Biomed Pharmacother. doi: 10.1016/j.biopha.2020.110009.

View post:
Updates on Single, Combination Precision Medicine in Targeted Cancer Therapy - AJMC.com Managed Markets Network

ESCONDIDO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, will host a webinar on how to bring supercomputing performance to data at the edge for AI applications with leaders from NVIDIA and Marvell.

The panel will be moderated by OSS chief sales and marketing officer, Jim Ison. He will be joined by Ying Yin Shih, director of product management at NVIDIA and Larry Wikelius, vice president, ecosystem and solutions at Marvell.

Topic: AI at the Edge: Bringing Supercomputing Performance to the DataThe webinar will discuss solving hard problems in defense, aerospace, autonomous vehicles, security, personalized medicine and more by leveraging massive NVIDIA enabled AI solutions designed for the unique size, power and rugged requirements of the edge.

A new computing paradigm is emerging that puts computing and storage resources for AI and HPC workflows not in the datacenter but on the edge near the data source. Applications continue to emerge for this new paradigm in diverse areas, including autonomous vehicles, precision medicine, battlefield command and control, industrial automation, and media and entertainment.

The common elements of these solutions are high data rate acquisition, high-speed and low-latency storage, and efficient, high-performance compute analyticsall configured to meet the unique environmental conditions of edge deployments.

This webinar will explain the challenges and solutions for meeting these requirements by describing real world use cases being developed and deployed today. OSS will present use cases of its edge-focused AI on the Fly products currently deployed in intelligence, surveillance and reconnaissance (ISR), genomic analysis, location-based entertainment, and autonomous driving.

NVIDIA and Marvell will describe their collaboration to support NVIDIA CUDA and CUDA-X software platform on the high performance, low power Arm architecture with Marvells ThunderX2 server processor. The combination provides a powerful tool in the expanding set of solutions for edge-focused AI infrastructure. The panel will discuss how CUDA for Arm provides an effective AI on the Fly building block for edge-oriented solutions where high performance, memory bandwidth and low power are essential.

Date: Wednesday, May 6 Time: 9:00 a.m. PDT

Register for this webinar today, click here.

About One Stop SystemsOne Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance computing modules and systems, including customized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator storage software. These products are used for deep learning, AI, defense, finance and entertainment applications, and empower scientists, engineers, creators and other professionals to push the boundaries of their industries.

OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for OEMs and government customers. The company enables AI on the Fly by bringing AI datacenter performance to the edge and on mobile platforms, and by addressing the entire AI workflow, from high speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to http://www.onestopsystems.com.

Forward-Looking StatementsOne Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the use of our products and applications in certain industries. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including, without limitation: risks associated with the fitness of One Stop Systems products and applications in certain industry sectors such as for autonomous vehicles, precision medicine, battlefield command and control, industrial automation, and media and entertainment; risks associated with the performance of our products that are combined into a third partys product, system, or application; and other risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trademarksin thispress releaseare theproperty of their respective owners.

Media Contact: Katie RiveraOne Stop Systems, Inc. Tel (760) 745-9883Email contact

Investor Relations:Ronald Both or Grant StudeCMATel (949) 432-7557 Email contact

Continued here:
OSS to Host AI at the Edge Webinar with Leaders from NVIDIA and Marvell - GlobeNewswire

As the coronavirus pandemic continues to spread around the globe, the world is facing an unprecedented crisis, carrying enormous financial and social costs unimaginable until recently. But these great difficulties also present opportunities for bold innovators to bypass bureaucracy and leapfrog their competitors, while rolling out revolutionary products at speed and scale. With the right leadership, innovative startups can use downturns to their advantage in the midst of economic crises. This can clearly be seen in Israels unique digital health innovation ecosystem.

The digital health sector is prospering in Israel. With more than 550 innovative companies, technology hubs, R&D centers, incubators, and multinational corporations in this space, the vibrant Israeli digital health ecosystem has more than doubled in size from 2011 to 2019. Now, the Startup Nation is leading the way with hundreds of scientists, innovators and investors racing to fight coronavirus. From faster diagnosis of COVID-19, to virtual homecare monitoring, to personalized medicine solutions disruptive technologies are being created and passed into service at extraordinary rates.

As historian Yuval Noah Harari recently stated, decisions that in normal times could take years of deliberation are passed in a matter of hours In normal times, governments, businesses and educational boards would never agree to conduct such experiments. But these arent normal times. Despite the risks these somewhat hurried experiments could pose to data privacy and potentially other civil liberties, many believe this may be a once-in-a-plaguetime opportunity for Israeli entrepreneurs to fast-track entry of novel technologies into the market.

Absence of epidemiological data

In order to roll out cutting-edge solutions and interventions, we vitally need one thing: easy collection and shared access to reliable global medical data and insights. Experts claim that Big Data - which analyzes large and complex datasets should be at the heart of the efforts to understand and forecast the impact that COVID-19 and other pandemics will have on all of us. But surprisingly, in todays digital world, such open flow of information barely exists in the healthcare sector.

Shutterstock

One of the most debated issues is the absence of epidemiological data on COVID-19 incidences in representative random samples of the general population. Just recently, the US Centers for Disease Control and Prevention announced new stunning evidence about the state of the virus: of 397 asymptomatic people tested at Bostons homeless shelter Pine Street Inn, 146 people, or 37%, tested positive for coronavirus. This is at a time when confirmed positive cases in Massachusetts amounted to roughly 0.4%. Similarly, researchers from Stanford University who recently tested 3,300 Californians in Santa Clara County for antibodies, found that the number of people who had been infected in the county was between 50 and 85 times higher than the confirmed case total.

Better predict the next outbreak

Equally important is the lack of clinical data on possible COVID-19 therapies. Three months into the outbreak, physicians are fighting an elusive enemy blindfolded, turning to experimental treatments without knowing where to look and which strategies are most likely to work.

The lack of both epidemiological and clinical data has become a huge concern for Dr. Dekel Taliaz, CEO of personalized medicine startup Taliaz, and President of Digital Health Technologies Israel, an umbrella body representing the digital health ecosystem in Israel. We would be in a totally different place if we had better access to up-to-date global medical insights, he says. Rather than decisionmakers relying on outdated or irrelevant statistics, they would be able to make flexible decisions based on real-life conditions.

This, of course, applies to future outbreaks of COVID-19 and other pandemics, as it gives the world data and tools to be able to better predict and pinpoint the next outbreak.

Real-time insights can outpace coronavirus

Imagine a world in which, based on artificial intelligence and predictive analytics, tailored sets of protocols with different levels of rigor could be implemented for every city, county and neighborhood. This is where startups like Israels Diagnostic Robotics come in. Together with Israels Ministry of Health, Diagnostic Robotics monitors, models and predicts infection trends over time, including daily geographic spread of exposed, suspected, confirmed and deteriorating patients. These dynamic COVID-19 heat maps support forecasts of community-level risk and expected strain on healthcare resources.

Other groundbreaking innovations include Datos Healths new remote management system for home-quarantined COVID-19 cases; and Binah.ais real-time remote vital signs monitoring app, which allows anyone to easily measure oxygen saturation, respiration rate, heart rate and heart rate variability just by looking into a smartphone camera. And this is just the tip of the iceberg.

The novel coronavirus is highly contagious and spreads at higher rates than initially estimated, Dr. Taliaz says. This means we need to support the development of digital tools with real-time insights that can outpace coronavirus. Taliaz has developed an artificial intelligence platform that analyzes clinical, demographic and genetic data to help doctors reduce trial and error by prescribing the right medication from the outset.

Decisionmakers need data to effectively conduct public health interventions

Considering the urgency and profound implications of the coronavirus pandemic, healthcare systems must act now, and some already do: the Israeli Ministry of Health has already opened access to its coronavirus database; similarly, South Korea has released a new website portal to support a global research collaboration on COVID-19.

While these are substantial strides forward, much information is still missing. Healthcare innovation is the backbone that will help us adapt, respond and overcome this pandemic. It is therefore critical to put in place an immediate global plan that makes the secure collection and sharing of anonymized, encrypted medical data a top priority. Now is the time to provide decisionmakers with the valuable data they need to transform existing rigid, static protocols into dynamic, data-driven public health interventions. If we choose global cooperation, we may not only protect our deeply interconnected world from coronavirus, but also prepare it for future pandemics.

Danielle Shapira of Maverick Ventures Israel contributed to this article. Maverick has invested in Diagnostic Robotics and Binah.ai.

Link:
Why Greater Access To Global Data Is Vital To The Fight Against COVID-19 And Future Pandemics - Forbes

The global healthcare industry is booming. As per recent research, it is expected to cross the $2 trillion mark this year, despite the sluggish economic outlook and global trade tensions. Human beings, in general, are living longer and healthier lives.

There is increased awareness about living organ donation. Robots are being used for gallbladder removals, hip replacements, and kidney transplants. Early diagnosis of skin cancers with minimum human error is a reality. Breast reconstructive surgeries have enabled breast cancer survivors to partake in rebuilding their glands.

All these jobs were unthinkable sixty years ago. Now is an exciting time for the global health care sector as it progresses along its journey for the future.

However, as the worldwide population of 7.7 billion is likely to reach 8.5 billion by 2030, meeting health needs could be a challenge. That is where significant advancements in machine learning (ML) can help identify infection risks, improve the accuracy of diagnostics, and design personalized treatment plans.

source: Deloitte Insights 2020 global health care outlook

In many cases, this technology can even enhance workflow efficiency in hospitals. The possibilities are endless and exciting, which brings us to an essential segment of the article:

Do you understand the concept of the LACE index?

Designed in Ontario in 2004, it identifies patients who are at risk of readmission or death within 30 days of being discharged from the hospital. The calculation is based on four factors length of stay of the patient in the hospital, acuity of admission, concurring diseases, and emergency room visits.

The LACE index is widely accepted as a quality of care barometer and is famously based on the theory of machine learning. Using the past health records of the patients, the concept helps to predict their future state of health. It enables medical professionals to allocate resources on time to reduce the mortality rate.

This technological advancement has started to lay the foundation for closer collaboration among industry stakeholders, affordable and less invasive surgery options, holistic therapies, and new care delivery models. Here are five examples of current and emerging ML innovations:

From the initial screening of drug compounds to calculating the success rates of a specific medicine based on physiological factors of the patients the Knight Cancer Institute in Oregon and Microsofts Project Hanover are currently applying this technology to personalize drug combinations to cure blood cancer.

Machine learning has also given birth to new methodologies such as precision medicine and next-generation sequencing that can ensure a drug has the right effect on the patients. For example, today, medical professionals can develop algorithms to understand disease processes and innovative design treatments for ailments like Type 2 diabetes.

Signing up volunteers for clinical trials is not easy. Many filters have to be applied to see who is fit for the study. With machine learning, collecting patient data such as past medical records, psychological behavior, family health history, and more is easy.

In addition, the technology is also used to monitor biological metrics of the volunteers and the possible harm of the clinical trials in the long-run. With such compelling data in hand, medical professionals can reduce the trial period, thereby reducing overall costs and increasing experiment effectiveness.

Every human body functions differently. Reactions to a food item, medicine, or season differ. That is why we have allergies. When such is the case, why is customizing the treatment options based on the patients medical data still such an odd thought?

Machine learning helps medical professionals determine the risk for each patient, depending on their symptoms, past medical records, and family history using micro-bio sensors. These minute gadgets monitor patient health and flag abnormalities without bias, thus enabling more sophisticated capabilities of measuring health.

Cisco reports that machine-to-machine connection in global healthcare is growing at a rate of 30% CAGR which is the highest compared to any other industry!

Machine learning is mainly used to mine and analyze patient data to find out patterns and carry out the diagnosis of so many medical conditions, one of them being skin cancer.

Over 5.4mn people in the US are diagnosed with this disease annually. Unfortunately, the diagnosis is a virtual and time-taking process. It relies on long clinical screenings, comprising a biopsy, dermoscopy, and histopathological examination.

But machine learning changes all that. Moleanalyzer, an Australia-based AI software application, calculates and compares the size, diameter, and structure of the moles. It enables the user to take pictures at predefined intervals to help differentiate between benign and malignant lesions on the skin.

The analysis lets oncologists confirm their skin cancer diagnosis using evaluation techniques combined with ML, and they can start the treatment faster than usual. Where experts could identify malignant skin tumors, only 86.6% correctly, Moleanalyzer successfully detected 95%.

Healthcare providers have to ideally submit reports to the government with necessary patient records that are treated at their hospitals.

Compliance policies are continually evolving, which is why it is even more critical to ensure the hospital sites to check if they are being compliant and functioning within the legal boundaries. With machine learning, it is easy to collect data from different sources, using different methods and formatting them correctly.

For data managers, comparing patient data from various clinics to ensure they are compliant could be an overwhelming process. Machine learning helps gather, compare, and maintain that data as per the standards laid down by the government, informs Dr. Nick Oberheiden, Founder and Attorney, Oberheiden P.C.

The healthcare industry is steadily transforming through innovative technologies like AI and ML. The latter will soon get integrated into practice as a diagnostic aid, particularly in primary care. It plays a crucial role in shaping a predictive, personalized, and preventive future, making treating people a breeze. What are your thoughts?

Image: Depositphotos.com

Read more from the original source:
How Machine Learning Is Redefining The Healthcare Industry - Small Business Trends

CHI, the Cleveland Health Institute, is dedicated to delivering health care with compassion, humility and integrity. We offer a full spectrum of services ranging from triaging acute care to diagnosing and managing chronic illness to practicing precise personalized medicine. We do this by emphasizing gene compatible lifestyles through predictive testing, preventive measures, personalized programs and patient education, enabling true partnership and full participation in creating health.

We have adopted the following in order to continue to care for our staff and CHI patients:

Telemedicine for scheduled consultations and follow up appointments

Secure email or fax for all administrative forms, patient histories and lab requisitions

Mail test kits with pre-paid labels to ship directly to labs

COVID-19 prevention recommendations and kit

Ship directly to our patients or provide curb side pickup for pharmaceutical grade targeted nutritional support for the immune system or to balance your neuroendocrine system to help with fear, anxiety, fatigue or depression

Emergency patient phone service 24/7

Upgrading CLE-CHI.com featuring an online store, contact us and ask your questions and the library of current relevant featured articles, like COVID 29 and Creating Maximum Immunity: A Vaccine will not Cure the Problem

Dr. Tonya S. Heyman, Medical Director

Here is the original post:
CHI, the Cleveland Health Institute - Cleveland Jewish News

Personalized medicine companies seek to combat the scourge of cancer through personalized care, driving interest in patient-specific treatments that require testing.

The global personalized medicine (PM) market size was estimated at USD 1.57 trillion in 2018 and is anticipated to expand at a CAGR of +11% during the forecast period.

Personalized medicine promises a paradigm shift in diagnosis and care delivery as the treatment is based on data leveraged from a holistic view of an individual patient. Proliferation of sequencing methodologies, especially Next Generation Sequencing (NGS), due to rising cost of sequencing and development of Human Genome Project in genomics field is expected to drive the market.

Get Sample Copy of this Report Includes @: https://www.theresearchinsights.com/request_sample.php?id=45572

Key players profiled in the report include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corporation; Danaher Corporation (Cepheid, Inc.);Decode Genetics, Inc.;Genelex Corporation; Exagen Diagnostics, Inc.; Precision Biologics, Inc.; QIAGEN; Celera Diagnostics LLC; and Biogen, Inc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Personalized Medicine market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

In the geographic segmentation, the regions such as North America, Middle East & Africa, Asia Pacific, Europe and Latin America are given major importance. The top key driving forces of Personalized Medicine market in every particular market is mentioned with restraints and opportunities. The restraints are also given a counter act which prove to be an opportunity for this market during the forecast period of 2020 to 2026 respectively.

Get Discount on up to 40%: https://www.theresearchinsights.com/ask_for_discount.php?id=45572

Personalized Medicine market is also explained to the clients as a holistic snapshot of a competitive landscape within the given competitive forecast period. A comparative analysis of regional players and segmentations, which helps readers get a better understanding of the areas and resources with better understanding.

This report provides:

1) An overview of the global market for Personalized Medicine Market and related technologies.

2) Analyses of global market trends, with data from 2017, estimates for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2026.

3) Identifications of new market opportunities and targeted promotional plans for Global Personalized Medicine Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Table of Content

1 Introduction

2 Market Research Tactics

3 Market Summary

4 Quality Market Insights

5 Personalized Medicine Market Overview

6 Regulatory Market Synopsis

7 Personalized Medicine Market, By Application Analysis:

8 Personalized Medicine Market, By product Analysis:

9 Personalized Medicine Market, By End User Analysis:

10 Personalized Medicine Market, By Geographic Region

11 Competitive Landscape

12 Company Profiles

You Can Browse Full Report: https://www.theresearchinsights.com/enquiry_before_buying.php?id=45572

About usThe Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact usRobinSales manager+91-996-067-0000[emailprotected]

Continue reading here:
Personalized Medicine Market Is Projected To Expand At A Robust CAGR Of +11% By 2026 Analysis by Industry Outlook, Estimated Size, Valuable Share,...

Dr. Natalia Echeverri, (R) uses a swab to gather a sample from the nose of Sammy Carpenter, who said he is homeless, to test him for COVID-19 on April 17, 2020 in Miami, Florida.

Joe Raedle | Getty Images

An ambitious new plan to radically increase the number of coronavirus tests in the United States would see up to 30 million people screened each week and cost up to $100 billion to implement, a private foundation said Tuesday.

But that pricey effort for what one expert called "the largest public health testing in history" is necessary to stem the $300 billion to $400 billion in American economic losses each month as a result of the Covid-19 pandemic, the Rockefeller Foundation said.

It said the sooner coronavirus tests become much more widely available, the quicker the U.S. economy can start getting back to normal.

"We do have the capacity to do that, and we've got the resources to do that," said Dr. Michael Pellini, managing partner of health venture firm Section 32 and board member of the Personalized Medicine Coalition, who contributed to the foundation's new plan.

"Yes, it's ambitious, but at this point we've got to do it," Pellini said. "We have to fix testing in this country to enable our workforce to be deployed once again."

The plan comes amid calls by numerous experts and by CEOs to boost coronavirus testing to make sure businesses and social events can reopen safely without sparking second and third waves of virus outbreaks.

Amazon CEO Jeff Bezos, in a note to shareholders last week, wrote:Regular testing on a global scale, across all industries, would both help keep people safe and help get the economy back up and running."

Rockefeller Foundation President Dr. Rajiv Shah said: "We envision an America where everyone who needs a test can get one."

Rajiv Shah, president of The Rockefeller Foundation

Jason Alden | Bloomberg | Getty Images

"The Rockefeller Foundation believes that testing access is critical to scaling up our lives and economy," Shah said during a conference call with reporters Monday, when the total number of confirmed coronavirus cases reached more than 766,600, and the number of related fatalities approached 41,000.

He called the up-to-$100 billion cost of the effort "a modest investment," given the amount of monthly economic losses to the nation, as well as the societal costs related to the outbreak, which could end up increasing rates of suicides, alcoholism and domestic violence.

While the goal of the testing plan is to build a state-led national program, the foundation said funding for it likely can come from federal funds through agencies or grants.

The foundation itself is investing $15 million to help kick off the effort, which includes supporting cities that are among the first to adopt the plan's recommendations.

The Rockefeller Foundation,which is a major philanthropicdonorin areas including health and science, told CNBC last week that it had been in contact with the Trump administration, national groups of governors and mayors and leading American corporations as it prepared the recommendations.

The foundation's plan lays out a strategy for tripling, within the next eight weeks, the existing 1 million coronavirus test per week now being done by maximizing efficiencies in testing capacity.

After that, the foundation calls for multiplying those 3 million tests per week by at least 10 times to get to at least 30 million tests each week within the next six months.

Reaching that level will entail, among other things, removing regulatory barriers to approval for new point-of-care and home-test kits, and ensuring payments for labs performing the tests.

The Rockefeller plan says that more testing must be done to accurately capture the level of Covid-19 infections in the U.S.

"In Taiwan, there have been 132 tests conducted for every confirmed case. In Australia, the number is 62. In the United States, it is five," an executive summary of the plan notes.

"The unfortunate conclusion from this comparison is that the country's actual number of infections may be 15- to 20-times higher than the reported number of confirmed cases," the summary says.

"In short, the United States needs to increase the current level of 1 million tests per week by at least 10-fold and preferably 20-fold to adequately monitor the pandemic."

The plan notes that "given the commercial uncertainties inherent in this 10-fold increase in production" it is likely the federal government would need to activate the Defense Production Act to compel production of tests.

The plan calls for the creation of an Emergency Network for Covid-19 Testing to coordinate and underwrite the testing market with the use of leverage from public-private credit guarantees and other tools.

The second part of the plan envisions a paid Covid Community Healthcare Corps of 100,000 to 300,000 people to perform the high number of texts and conduct "contact tracing," or reaching out to individuals who have been around infected people and testing them as well.

The third part is a common data and digital platform to support the first two objectives by sharing "real-time analyses of resource allocations, disease tracing results and patient medical records."

New York University professor Paul Romer, who shared the 2018 Nobel Prize in economics, said the need for a huge increase in the number of coronavirus tests is driven not only by the need to stanch current economic losses but to prevent permanent damage to U.S. economic output when the country exits recession.

"Our future capacity to produce" is lower because of the economic cost of the pandemic "and it deteriorates with each month of delay," said Romer, who contributed to the Rockefeller Foundation's plan.

But Romer said the solution to the testing problem lies in the current system, which needs to be reorganized and incentivized financially to produce enough tests.

"We're really not constrained on the supply side, but we are constrained by what we're willing to pay," Romer said.

"We just need to pay people and let them have to option to provide these tests."

Romer made the analogy of the government saying that there needed to be 300 million soft drinks made one day.

No one would step up to make the drinks for free, he suggested, but they would be made if the government agreed to pay for them.

See the rest here:
Coronavirus: New plan would test 30 million per week and cost up to $100 billion, but 'we've got to do it' - CNBC

Dublin, April 24, 2020 (GLOBE NEWSWIRE) -- The "North America Cell Expansion Market to 2027 - Regional Analysis and Forecasts by Product; Cell Type; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

The cell expansion market in North America is anticipated to reach USD 14,697.41 million by 2027 from USD 4,522.07 4 million in 2019; it is projected to grow at a CAGR of 15.9% during 2020-2027. The growth of the market is attributed to the increasing prevalence of cancer, rising number of new product launches, and increasing inclination of patients toward regenerative and personalized medicines. Also, growing R&D expenditure on cancer research is likely to have a positive impact on the growth of the market in the coming years. In addition, technological advancements in the pharmaceuticals industry and extensive developments in drug discovery are likely to stimulate the growth of cell expansion market in North America during the forecast period.

Cell expansion is the large-scale artificial production of daughter cells from a single cell, and the process is carried out to support the medical research. It plays a critical role in exploring a wider range of benefits and applications of fully differentiated stem cell cultures for their use in therapeutics, drug screening, or advanced research.

R&D is a significant part of a majority of pharmaceutical and biotech companies; they focus on R&D to come up with new molecules with the most significant medical and commercial potential for various therapeutic applications. The companies invest big amounts in these activities to deliver innovative, high-quality products to the market. Moreover, as per the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expense of biopharmaceutical companies surged from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015.

Several government organizations are working on enhancing the detection methods and treatment procedures of cancer in the region. The National Cancer Institute (NCI) spends on various categories of the treatment, including specific cancer sites, cancer types, and cancer-related diseases, as well as types of NCI research mechanisms. The NCI allocated the funds of ~US$ 208.4 million for cell expansion research in 2017 from their total budget of US$ 5,636.4 million in that year for cancer research studies. Therefore, the growing R&D expenditure on cancer research by these companies is expected to provide them with opportunities for business expansion.

The North American cell expansion market has been segmented on the basis of cell type into human cells and animal cells. The human cells segment held a larger share of the market in 2018, and it is also projected to register a higher CAGR in it during the forecast period. Rise in research activities for the treatment of cancer is expected to offer considerable growth opportunities for the human cell expansion market players.

A few of the important secondary sources referred to for preparing this report on the cell expansion market are World Health Organization (WHO), Food and Drug Administration (FDA), Canadian Cancer Society, Centers for Disease Control and Prevention (CDC), and American Cancer Society.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 North America Cell Expansion Market - By Product1.3.2 North America Cell Expansion Market - By Cell Type1.3.3 North America Cell Expansion Market - By Application1.3.4 North America Cell Expansion Market - By End User1.3.5 North America Cell Expansion Market - By Country

2. North America Cell Expansion Market- Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. North America Cell Expansion Market - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 Cell Expansion Market - North America PEST Analysis4.3 Expert Opinion

5. North America Cell Expansion Market - Key Market Dynamics5.1 Key Market Drivers5.1.1 Patient shift towards regenerative medicines5.1.2 Increasing number of patients suffering with cancer5.2 Key Restraints5.2.1 Risk of contamination associated with the cell expansion process5.3 Key Market Opportunities5.3.1 Growing R&D Expenditure for Cancer Research5.4 Future Trend5.4.1 Extensive development in drug discovery5.5 Impact Analysis

6. Cell Expansion Market - North America Analysis6.1 North America Cell Expansion Market Revenue Forecasts and Analysis6.2 Positioning Of Key Players

7. North America Cell Expansion Market Analysis And Forecasts To 2027 - Product7.1 Overview7.2 North America Cell Expansion Market, By Product 2018 & 2027 (%)7.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Product (US$ Mn)7.2.1.1 North America Consumables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.1.1 North America Disposables Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.2.1.2 North America Instruments Market Revenue and Forecasts to 2027, By Type (US$ Mn)7.3 Consumables7.3.1 Overview7.3.2 North America Consumables Market Revenue and Forecast to 2027 (US$ Mn)7.3.3 Reagents, Media & Serum7.3.3.1 Overview7.3.3.2 North America Reagents, Media & Serum Market Revenue and Forecast to 2027 (US$ Mn)7.3.4 Disposables7.3.4.1 Overview7.3.4.2 North America Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.3 Culture Tissue Flasks7.3.4.3.1 Overview7.3.4.3.2 North America Culture Tissue Flasks Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.4 Bioreactor Accessories7.3.4.4.1 Overview7.3.4.4.2 North America Bioreactor Accessories Market Revenue and Forecast to 2027 (US$ Mn)7.3.4.5 Other Disposables7.3.4.5.1 Overview7.3.4.5.2 North America Other Disposables Market Revenue and Forecast to 2027 (US$ Mn)7.4 Instruments7.4.1 Overview7.4.2 North America Instruments Market Revenue and Forecasts to 2027 (US$ Mn)7.4.3 Cell Expansion Supporting Equipment7.4.3.1 Overview7.4.3.2 North America Cell Expansion Supporting Equipment Market Revenue and Forecast to 2027 (US$ Mn)7.4.4 Bioreactors7.4.4.1 Overview7.4.4.2 North America Bioreactors Market Revenue and Forecast to 2027 (US$ Mn)7.4.5 Automated Cell Expansion Systems7.4.5.1 North America Automated Cell Expansion Systems Market Revenue and Forecast to 2027 (US$ Mn)

8. North America Cell Expansion Market Analysis And Forecasts To 2027 - Cell Type8.1 Overview8.2 North America Cell Expansion Market, By Cell Type 2018 & 2027 (%)8.2.1 North America Cell Expansion Market Revenue and Forecasts to 2027, By Cell Type (US$ Mn)8.3 Human Cells8.3.1 Overview8.3.2 North America Human Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.3 Adult Stem Cells8.3.3.1 Overview8.3.3.2 North America Adult Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.4 Induced Pluripotent Stem Cells8.3.4.1 Overview8.3.4.2 North America Induced Pluripotent Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.5 Embryonic Stem Cells8.3.5.1 Overview8.3.5.2 North America Embryonic Stem Cells Market Revenue and Forecast to 2027 (US$ Mn)8.3.6 Differentiated Cells8.3.6.1 Overview8.3.6.2 North America Differentiated Cells Market Revenue and Forecast to 2027 (US$ Mn)8.4 Animal Cells8.4.1 Overview8.4.2 North America Animal Cells Market Revenue and Forecast to 2027 (US$ Mn)

9. North America Cell Expansion Market Analysis- By Application9.1 Overview9.2 North America Cell Expansion Market, By Application 2018 & 2027 (%)9.3 Regenerative Medicine and Stem Cell Research9.4 Cancer and Cell-based Research9.5 Other Applications

10. North America Cell Expansion Market Analysis- By End User10.1 Overview10.2 North America Cell Expansion Market, By End User 2018 & 2027 (%)10.3 Biopharmaceutical And Biotechnology Companies10.4 Research Institutes10.5 Cell Banks10.6 Other End Users

11. Cell Expansion Market Revenue And Forecasts To 2027 - Geographical Analysis11.1 North America Cell Expansion Market, Revenue and Forecast to 202711.1.1 North America Cell Expansion Market, Revenue and Forecast to 2027 (US$ Mn)11.1.2 North America Cell Expansion Market, Revenue and Forecast to 2027, By Product (US$ Mn)11.1.2.1 North America Consumables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.1.1 North America Disposables Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.2.2 North America Instruments Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.3 North America Cell Expansion Market, Revenue and Forecast to 2027, By Cell Type (US$ Mn)11.1.3.1 North America Human Cell Market, Revenue and Forecast to 2027, By Type (US$ Mn)11.1.4 North America Cell Expansion Market, Revenue and Forecast to 2027, By Application (US$ Mn)11.1.5 North America Cell Expansion Market, Revenue and Forecast to 2027, By End User (US$ Mn)11.1.6 North America Cell Expansion Market, Revenue and Forecast to 2027, By Country (%)11.1.7 US11.1.8 Canada11.1.9 Mexico

12. North America Cell Expansion Market- Industry Landscape12.1 Overview12.2 Growth Strategies In The Cell Expansion Market, 2017-201912.3 Organic Growth Strategies12.3.1 Overview12.3.1.1 Recent Organic Developments By Players In The Cell Expansion Market12.4 Inorganic Growth Strategies12.4.1 Overview12.4.2 Recent Developments By Players In The Cell Expansion Market

13. Global Cell Expansion Market-Key Company Profiles13.1 BD13.1.1 Key Facts13.1.2 Business Description13.1.3 Financial Overview13.1.4 Product Portfolio13.1.5 SWOT Analysis13.1.6 Key Developments13.2 Merck KGaA13.3 Thermo Fisher Scientific, Inc.13.4 Terumo Corporation13.5 General Electric Company13.6 Corning Incorporated13.7 Miltenyi Biotec13.8 Danaher13.9 Lonza13.10 STEMCELL Technologies, Inc.

14. Appendix14.1 About the Publisher14.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/gq37sj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:
Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - GlobeNewswire

NEW YORK, April 22, 2020 /PRNewswire/ --

KEY FINDINGSThe global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028. The prominent drivers of market growth are estimated to be the rising big data in the healthcare industry, the growing use of AI in genetics, the emergence of personalized medicine in tests for clinical decision making, along with the creation of a real-time monitoring system due to AI.

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

MARKET INSIGHTSThe utilization of AI in healthcare entails the use of software and algorithms for estimating the human perception for analyzing complex medical data, along with the relationship between treatments or prevention techniques and patient outcomes.The growing demand for real-time monitoring system is one of the key aspects propelling the growth of the global artificial intelligence in healthcare market.

The real-time monitoring devices like health monitoring devices or indicators track real-time health data of patients, which is increasing the demand for AI in healthcare.The devices also drive the relevancy of data interpretation and aid in reducing the time the patients spend in piecing data output.

In healthcare, the devices help in detecting and preventing undesirable patient outputs. The growing number of mobile devices integrated with artificial intelligence assists in the prediction of future outcomes with regard to health, which further benefits market growth.Medical practitioners are reluctant to adopt AI-based technologies, and this is restraining the growth of the market.The reluctance is because of the lack of data that identifies healthcare decisions.

Also, from a diagnostics point of view, AI systems fare less in terms of efficiency in comparison to conventional methods.The companies in the market are competing against each other by providing the same characteristics and similar prices.

The competitive rivalry is projected to be high during the forecast period.

REGIONAL INSIGHTSThe geographical segmentation of the global artificial intelligence in healthcare market includes the analysis of Europe, North America, Asia Pacific, and the rest of the world.Inkwood Research estimates the Asia Pacific region to be the fastest-growing region by the end of the forecast period.

The invention of new technologies, the presence of countries like China, Japan, Australia, and India, and the thriving artificial intelligence market, are the factors propelling the growth of the market.

COMPETITIVE INSIGHTSSome of the prominent companies operating in the market are Enlitic Inc, Next IT Corporation, Recursion, Welltok, GE Healthcare, Microsoft Corporation, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned1. DEEP GENOMICS INC2. ENLITIC INC3. GE HEALTHCARE4. GENERAL VISION INC5. GOOGLE6. IBM CORPORATION7. ICARBONX8. INTEL CORPORATION9. MICROSOFT CORPORATION10. NEXT IT CORPORATION11. NVIDIA CORPORATION12. ONCORA MEDICAL13. RECURSION PHARMACEUTICALS INC14. STRYKER CORPORATION15. WELLTOK INC

Read the full report: https://www.reportlinker.com/p05242360/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-artificial-intelligence-in-healthcare-market-is-set-to-register-growth-projecting-a-cagr-of-38-05-during-the-forecast-period-2020-2028--301045674.html

SOURCE Reportlinker

More:
The global artificial intelligence in healthcare market is set to register growth, projecting a CAGR of 38.05% during the forecast period, 2020-2028 -...

Its pretty hard to ignore the impact of Covid-19 on the global and domestic economy. But the shutdown in the U.S. economy, while swift, was also swiftly managed by the administration and Congress, as well as the Federal Reserve.This has helped buoy the markets after a precipitous initial drop. And it has allowed enough time for investors to process everything that has happened and reset their expectations looking away from certain risks and into cleaning-supply companies and biotech stocks.

Previous to Covid-19, there was the feeling the economy was nearing recession sometime this year. Now were in one.

However, this remains an uneven market. Big stocks like Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) are doing even better under these difficult conditions. But other consumer stocks arent.

Thats why I wanted to talk about an opportunity that doesnt have to do with consumer-driven stocks the seven beautiful biotech stocks to buy here. These companies are set up to endure long drug approval processes that happen over good times and bad.

Theyre built to be immune from general market forces, especially the big one these days consumer spending and to benefit from powerful technology thats popping up in all kinds of industries.

Source: Catalin Rusnac/ShutterStock.com

CRISPR is a Swiss biotech that is one of the leaders in CRISPR technology. This is a new and fast-growing field. CRISPR (it stands for clustered regularly interspaced short palindromic repeats) is a DNA segment containing short repetitions of base sequences.

By using these, scientists are learning to identify where there is a break in the pattern that may signal a disease and then repair (or edit) that sequence. This is a revolutionary concept in treating disease, since it is the first step toward personalized medicine.

Currently the research is hoping to build treatments to help battle many different cancers and other diseases. But eventually the technology can be applied to a much broader field of needs.

The company is well funded and will continue to make a difference, even sequencing Covid-19.

The stock is up 37% in the past year and over 30% in the past month.

Source: Pavel Kapysh / Shutterstock.com

Acceleron is a biopharmaceutical company that has been around since 2003. Last year was a wild ride for the firm, and the volatility continued into 2020.

In September, one of its drugs in trials was rejected by the FDA and the stock tanked. Then, shortly after that, its drug luspatercept, which treats a rare blood disorder, was approved.

And then, in late January, data from a Phase 2 trial of another drug it has in the approval process for pulmonary arterial hypertension (PAH), showed significant positive results in treating the disorder. This is the kind of situation that can attract big buying pressure on Wall Street of the kind I want to see inGrowth Investor.

Needless to say, the stock is now up 134% in the past year, and 38% in the past month.

One of its largest shareholders is Bristol Myers Squibb (NYSE:BMY). Acceleron had been doing a lot of work with Celgene when BMY bought Celgene. This is a great partnership to have when looking to market, manufacture and distribute these new drugs.

Source: Shutterstock

Neurocrine Bioscienceshas been in business for over 25 years and specializes in developing treatments for people suffering with neurological, endocrine and psychological disorders.

It currently has treatments for tardive dyskinesia and endometriosis. It has candidates for Parkinsons, uterine fibroids and congenital adrenal hyperplasia. Last year, there was talk that Biogen (NASDAQ:BIIB) may have been looking at NBIX as an acquisition to build on its own work in some of these sectors.

Its a solid company that has a good balance of revenue-generating drugs and a solid, focused drug pipeline. Neurocrine has a unique niche and will remain an attractive takeover target for larger pharmaceutical companies and biotechs.

The stock is up 17% for the past year, and 20% in the past month.

Source: Jarretera / Shutterstock.com

Galapagos is a Belgian company that specializes in small molecule and antibody therapies.

It was a solid performer and has been around for over 20 years. But its big break happened last year when Gileadapproached the company and offered it a $5 billion partnership deal. This brought the stock to the attention of many U.S. investors who hadnt paid much attention to it.

And by December, that partnership paid off. GILD filed with FDA for speedy review of filgotinib, a potential blockbuster drug that GLPG developed and had in Europe in Japan but not the U.S. The U.S. is the market where the money is made, since pricing is far more dynamic than in other countries.

The approval came in December. And this could mean big things for both companies. But since then, Covid-19 has taken the spotlight and Gileads remdesivir has been all the buzz.

GLPG stock is up over 80% in the past 12 months, and almost 45% in the past month. Its management has also been wise enough to partner with a genomics company that provides whats sometimes nicknamed the mother of all technologiesto help discover new treatments and drug combinations.

Source: Eyesonmilan / Shutterstock.com

Incyte has been around since the early 1990s and is good-sized biopharmaceutical company with a $21 billion market capitalization.

Currently it has two drugs in the marketplace, one of those is in the US. Its big drug is Jakafi (ruxolitinib), which treats a rare form of blood cancer and is also approved to manage acute graft-versus-host disease in adults.

It also has a drug that it acquired from ARIAD Pharmaceuticals for European distribution. Its Iclusig (ponatinib) is used to treat leukemia, and INCY stock hopes to make the drug available in the U.S. after approval from the FDA.

Incyte also has a good number of drugs in the pipeline and has the financial wherewithal to keep moving them forward, even now.

The stock is up 36% in the past 12 months, and over 60% in the past month.

Source: madamF / Shutterstock.com

Regeneron is one of those biotech stocks that has been a direct Covid-19 beneficiary.

It has a number of drugs in the market and around 30 drugs in its pipeline. It has been around since 1988 and has a $62 billion market cap, so this is no one-trick pony rolling the dice on a potential blockbuster. It has built its reputation over time, delivering solid drugs in important sectors.

But the added juice at this point is its arthritis drug Kevzara that it co-markets with Sanofi (NASDAQ:SNY). It has been given to patients in China and New York (the co-founder of Regeneron is from Queens) but the testing isnt broad enough to deliver any conclusive information.

Obviously, the bet on Kevzara being a treatment is just that, a bet. But it has brought more attention to REGN, which is a quality pharma. And Regeneron also has its eye on the big picture of next-generation technology to supercharge its genomics research at the Regeneron Genetics Center.

The stock is up almost 62% in the past year and up 22% in the past month.

Source: Michael Moloney / Shutterstock.com

Gilead has been a big name among biotech stocks for a long time. It was a key player in finding a treatment for HIV/AIDS. And was also a pioneer in finding a highly effective once-a-day regimen for hepatitis C.

While it still makes a good amount of money from these blockbusters, it hadnt had a big hit in a while and the stock flat-lined as investors wondered if its best days were behind it.

But it has made some interesting acquisitions and partnerships in the past couple years, one of those being with Galapagos.

And now, remdesivir is in two Phase 3 clinical trials as a treatment for Covid-19. This, along with the promising partnership with GLPG stock thats already delivering results, promises that GILD could beback in the running with two potential blockbusters. Even one would be great news.

The stock is on the move, up 30% in the past 12 months, and 13% in the past month. And it is still off its 2015 highs, so theres plenty of headroom if either or both these drug live up to their promise.

Gilead is one of the big kahunas in this space, and now a household name, thanks to the fight against Covid-19. It, too, is partnering with smaller labs to harness the power of the game-changing technology of our time: artificial intelligence (AI).

If artificial intelligence sounds futuristic, even far-fetched well, keep in mind, youre already using it every day. If youve ever usedAlphabets(NASDAQ:GOOG, NASDAQ:GOOGL) Google Assistant orApples(NASDAQ:AAPL) Siri if youve hadNetflix(NASDAQ:NFLX) recommend a movie orZillow(NASDAQ:Z) recommend a house even an email spam filter then youve used artificial intelligence.

In this new world of AI everywhere, data becomes a hot commodity.

As scientists find even more applications for artificial intelligence from hospitals to retail to self-driving cars its incredible to imagine how much data will be involved.

To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system. As one AI researcher from the University of South Florida puts it, data is the new oil.

To cash in, youll want the company that makes the brain that all AI software needs to function, spot patterns and interpret data.

Its known as the Volta Chip and itswhat makes the AI revolution possible.

You dont need to be an AI expert to take part.Ill tell you everything you need to know, as well as my buy recommendation, inmy special report forGrowth Investor,The A.I. Master Key. The stock is still under my buy limit price so youll want to sign up now. That way, you can get in while you can still do so cheaply.

Click here for a free briefing on this groundbreaking innovation.

Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system withreturns rivaling even Warren Buffett. In his latest feat, Louis discovered the Master Key to profiting fromthe biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.

Read the rest here:
7 Beautiful Biotech Stocks to Buy Here - Investorplace.com

Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall we believe in free public access to information. Although underresourced & primarily volunteer-based, we endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. Our goal and mission is to provide free and alternative access to impartial information, fighting media monopolization and adhering to honesty, neutrality, fairness, transparency and independence in collection and dissemination of information. It is a bumpy road with all sorties of difficulties. (Media ownership in Australia is one of the most concentrated in the world (more on this!). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn moreWe can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.If you like what we do & would like to buy us a coffee (or lots of coffees), please know it's greatly appreciated. All donations are kept completely private and confidential.Thank you very much in advance!

Read more:
Weizmann Institute of Science Began to Conduct Coronavirus Testing Today - Mirage News

Dublin, April 09, 2020 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.

The global precision medicine market is estimated to grow at a CAGR of 9.8% during the forecast period. Factors such as the increasing prevalence of cancer, central nervous system disorder, and respiratory diseases coupled with the increasing focus on researches focusing on the development of precision medicine are augmenting the market growth. Moreover, the growing focus on the biomarkers is promising ample opportunities for the growth of the personalized medicine market across the globe.

The report analyzes the global precision medicine market on the basis of technology, application, end-use, and geography. On the basis of technology, the market is genomics, transcriptomics, and epigenomics. Based on the application, the market is classified into oncology, neurology, immunology, and others. Based on the end-user, the market is classified into pharmaceutical companies, diagnostic companies, and healthcare IT companies.

The advancement in genomic and clinical science have established advanced prospects to further customize healthcare to every patient. The Center for Individualized Medicine at Mayo Clinic is practicing personalized medicine and using it to the complete spectrum of healthcare with the use of sophisticated techniques of molecular analysis and genomic sequencing. Microbiome Program by Mayo Clinic enables to understand the cause of transmitting the infection through bacteria. It investigates several questions under the program, such as if microbial communities in the colon could be responsible for irritable bowel symptoms and gluten sensitivity. In addition, it examines the colon organisms affect other body parts, including the joints. The program explores the genetic code of the microorganism of the body. It uses advanced techniques for profiling the microbiome of an individual to detect, prevent and diagnose infections and other diseases. These rising focus of medical centers towards microbiome program for personalized medicine is expanding the scope for the growth of the global personalized medicine market.

Geographically, the market is analyzed into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to contribute a significant market share in the global precision medicine industry over the forecast period. Increasing prevalence of cancer, respiratory diseases, and neurological disorders are augmenting the growth of the North America precision medicine market. Moreover, the presence of prominent institutes and market players focusing on the development of precision medicine through researches are also driving the market growth of the region.

Furthermore, the market is characterized by the presence of several players including F. Hoffmann La Roche Ltd., Abbott Laboratories Inc., Pfizer Inc., Qiagen NV, Teva Pharmaceutical Industries Ltd., Eagle Genomics, and many others. These players adopt various strategies to capitalize on market growth opportunities. For instance, in October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle the computational challenges of the genomics era. The aim of the partnership was to introduce the scale and power of the cloud to precision medicine, across the production of fundamental research and core services.

The Report Covers:

Key Topics Covered:

1. Report Summary1.1. Research Methods and Tools1.2. Market Breakdown1.2.1. By Segments1.2.2. By Geography

2. Market Overview and Insights2.1. Scope of the Report 2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion2.3. Rules & Regulations

3. Competitive Landscape3.1. Company Share Analysis3.2. Key Strategy Analysis3.3. Key Company Analysis3.3.1. F. Hoffmann La Roche Ltd.3.3.1.1. Overview3.3.1.2. Financial Analysis3.3.1.3. SWOT Analysis3.3.1.4. Recent Developments3.3.2. Abbott Laboratories Inc.3.3.2.1. Overview3.3.2.2. Financial Analysis3.3.2.3. SWOT Analysis3.3.2.4. Recent Developments3.3.3. Pfizer Inc.3.3.3.1. Overview3.3.3.2. Financial Analysis3.3.3.3. SWOT Analysis3.3.3.4. Recent Developments3.3.4. Qiagen NV3.3.4.1. Overview3.3.4.2. Financial Analysis3.3.4.3. SWOT Analysis3.3.4.4. Recent Developments3.3.5. Teva Pharmaceutical Industries Ltd. 3.3.5.1. Overview3.3.5.2. Financial Analysis3.3.5.3. SWOT Analysis3.3.5.4. Recent Developments

4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities

5. Market Segmentation5.1. Global Precision Medicine Market by Technology 5.1.1. Genomics5.1.2. Transcriptomics5.1.3. Epigenomics5.2. Global Precision Medicine Market by Application5.2.1. Oncology5.2.2. Neurology 5.2.3. Immunology5.2.4. Others (Respiratory)5.3. Global Precision Medicine Market by End-Use5.3.1. Pharmaceutical Companies5.3.2. Diagnostic Companies5.3.3. Healthcare IT Companies

6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe6.3. Asia-Pacific6.3.1. China6.3.2. Japan6.3.3. India6.3.4. Rest of Asia-Pacific6.4. Rest of the World

7. Company Profiles

Companies Mentioned

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/kdkbgk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Outlook on the Worldwide Precision Medicine Industry to 2025 - Growing Focus on Biomarkers is Promising Ample Opportunities - Yahoo Finance

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.

Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter, said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics. Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers. As an organization we have taken steps to advance these dual aims, and I am very proud of how the Myriad team has responded to the crisis.

In responding to the pandemic, Myriad has made several changes to its business practices to promote the safety of both customers and employees including ceasing in-office sales calls and implementing virtual selling, granting all non-essential personnel the ability to work from home, enabling direct sample collection for patients and implementing policies to improve laboratory personnel safety.

While the uncertain timeframe of the Coronavirus pandemic makes it difficult to predict future business trends for the company, the company will provide an update on its business, including the impact of COVID-19, on its next quarterly earnings call.

About Myriad GeneticsMyriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to maintaining the Companys global leadership in precision medicine and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of the Companys existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to the Companys ability to successfully transition from its existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for the Companys tests or the Companys ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the Company may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that the Company may not successfully develop new markets for its molecular diagnostic tests and pharmaceutical and clinical services, including the Companys ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying the Companys molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the Companys laboratory testing facilities; risks related to public concern over the Companys genetic testing in general or the Companys tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Companys ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to the Companys ability to successfully integrate and derive benefits from any technologies or businesses that it licenses or acquires; risks related to the Companys projections about the potential market opportunity for the Companys products; the risk that the Company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the Companys tests; the risk of patent-infringement claims or challenges to the validity of the Companys patents; risks related to changes in intellectual property laws covering the Companys molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the Company may be unable to comply with financial operating covenants under the Companys credit or lending agreements; the risk that the Company will be unable to pay, when due, amounts due under the Companys credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of the Companys most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Companys Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Story continues

See the article here:
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic - Yahoo Finance